{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:48:45Z","timestamp":1785426525192,"version":"3.56.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Cardiovascular disease (CVD), including atherosclerosis, valvular etiologies, or myocardial disorders, is typically asymptomatic for several years, representing an occult phase of illness. Readily available preventive treatments to reduce cholesterol and blood pressure, among other risk factors, have the potential to reduce and delay incident myocardial infarction (MI), heart failure, and cardiovascular (CV) deaths. Measurement of circulating levels of cardiac troponin T (cTnT) and troponin I (cTnI) released from cardiomyocytes, as a result of injury, has been the biochemical standard for the diagnosis of MI for more than 20\u2005years. The recent adoption of high-sensitivity (hs) assays, which are capable of measuring cTnT and I levels in more than 50% of the general population, has revealed a clear association between progressively higher biomarker levels and future CV events. In cross-sectional imaging studies, cTn levels measured by hs assays have also demonstrated correlations between elevated biomarker levels and occult CVD such as coronary artery disease and myocardial fibrosis. In this review, we provide evidence to consider measuring hs-cTnT and hs-cTnI to screen for patient CV risk and provide an example of a scenario in which such screening may improve outcomes through decision support for aggressive management of blood pressure.<\/jats:p>","DOI":"10.3389\/fcvm.2024.1350573","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T04:42:20Z","timestamp":1731559340000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Preclinical screening for cardiovascular disease with high-sensitivity cardiac troponins: ready, set, go?"],"prefix":"10.3389","volume":"11","author":[{"given":"Aya","family":"Awwad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashika","family":"Parashar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soahum","family":"Bagchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman Asad","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ogheneochuko","family":"Ajari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"deFilippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics\u20142023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"00050","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure","author":"Bozkurt","year":"2021","journal-title":"J Card Fail"},{"key":"B4","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S2213-8587(16)30196-6","article-title":"Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis","volume":"4","author":"Willeit","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jchf.2017.11.003","article-title":"High-sensitivity cardiac troponin and new-onset heart failure","volume":"6","author":"Evans","year":"2018","journal-title":"JACC: Heart Failure"},{"key":"B6","article-title":"CMS","year":""},{"key":"B7","volume-title":"Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease","author":"Micheel","year":"2010"},{"key":"B8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejim.2022.01.012","article-title":"High-sensitivity troponins for outcome prediction in the general population: a systematic review and meta-analysis","volume":"98","author":"Aimo","year":"2022","journal-title":"Eur J Intern Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jacc.2017.05.062","article-title":"High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular outcomes in 154,052 participants","volume":"70","author":"Willeit","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.hlc.2015.09.001","article-title":"Cardiac troponin and its relationship to cardiovascular outcomes in community populations\u2014a systematic review and meta-analysis","volume":"25","author":"Sze","year":"2016","journal-title":"Heart Lung Circ"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e5703","DOI":"10.1097\/MD.0000000000005703","article-title":"Prognostic value of basal high-sensitive cardiac troponin levels on mortality in the general population: a meta-analysis","volume":"95","author":"Van Der Linden","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1161\/CIRCULATIONAHA.119.043337","article-title":"Incorporation of biomarkers into risk assessment for allocation of antihypertensive medication according to the 2017 ACC\/AHA high blood pressure guideline","volume":"140","author":"Pandey","year":"2019","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamacardio.2021.3187","article-title":"Associations of high-sensitivity troponin and natriuretic peptide levels with outcomes after intensive blood pressure lowering: findings from the SPRINT randomized clinical trial","volume":"6","author":"Berry","year":"2021","journal-title":"JAMA Cardiology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1001\/jamacardio.2020.2981","article-title":"Clinical application of high-sensitivity troponin testing in the atherosclerotic cardiovascular disease framework of the current cholesterol guidelines","volume":"5","author":"Marston","year":"2020","journal-title":"JAMA Cardiology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1161\/CIRCULATIONAHA.116.025505","article-title":"High-sensitive cardiac troponin T as an early biochemical signature for clinical and subclinical heart failure","volume":"135","author":"Seliger","year":"2017","journal-title":"Circulation"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1104715","article-title":"Association of cardiac troponin T and growth differentiation factor 15 with replacement and interstitial cardiac fibrosis in community dwelling adults: the multi-ethnic study of atherosclerosis","volume":"10","author":"deFilippi","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1001\/jama.2010.1708","article-title":"Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults","volume":"304","author":"deFilippi","year":"2010","journal-title":"JAMA"},{"key":"B18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1001\/jamacardio.2016.0765","article-title":"Six-year change in high-sensitivity cardiac troponin T and risk of subsequent coronary heart disease, heart failure, and death","volume":"1","author":"McEvoy","year":"2016","journal-title":"JAMA Cardiology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cardfail.2022.05.013","article-title":"Longitudinal changes in cardiac troponin and risk of heart failure among black adults","volume":"29","author":"Saha","year":"2023","journal-title":"J Card Fail"},{"key":"B20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1415921","article-title":"Troponin and cardiac events in stable ischemic heart disease and diabetes","volume":"373","author":"Everett","year":"2015","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jacc.2013.08.1643","article-title":"Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID study (long-term intervention with pravastatin in ischaemic","volume":"63","author":"White","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1161\/CIRCULATIONAHA.117.032003","article-title":"Combining high-sensitivity cardiac troponin I and cardiac troponin T in the early diagnosis of acute myocardial infarction","volume":"138","author":"van der Linden","year":"2018","journal-title":"Circulation"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1161\/CIRCULATIONAHA.118.038772","article-title":"High-sensitivity troponin I and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC study","volume":"139","author":"Jia","year":"2019","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1161\/CIRCULATIONAHA.118.038529","article-title":"Cardiac troponin T and troponin I in the general population","volume":"139","author":"Welsh","year":"2019","journal-title":"Circulation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.jacc.2014.03.027","article-title":"Elevation of cardiac troponin T, but not cardiac troponin I, in patients with neuromuscular diseases: implications for the diagnosis of myocardial infarction","volume":"63","author":"Rittoo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1161\/CIRCULATIONAHA.121.058489","article-title":"Skeletal muscle disorders: a noncardiac source of cardiac troponin T","volume":"145","author":"du Fay de Lavallaz","year":"2022","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1373\/clinchem.2016.255109","article-title":"Cardiac troponin assays: guide to understanding analytical characteristics and their impact on clinical care","volume":"63","author":"Apple","year":"2017","journal-title":"Clin Chem"},{"key":"B28","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/clinchem\/hvz032","article-title":"Discrepancy between cardiac troponin assays due to endogenous antibodies","volume":"66","author":"Lam","year":"2020","journal-title":"Clin Chem"},{"key":"B29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2016.02.012","article-title":"High-sensitivity troponin T in relation to coronary plaque characteristics in patients with stable coronary artery disease; results of the ATHEROREMO-IVUS study","volume":"247","author":"Oemrawsingh","year":"2016","journal-title":"Atherosclerosis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/ATVBAHA.109.200394","article-title":"The extent of coronary atherosclerosis is associated with increasing circulating levels of high sensitive cardiac troponin T","volume":"30","author":"Laufer","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.hlc.2015.09.001","article-title":"Cardiac troponin and its relationship to cardiovascular outcomes in community populations\u2014a systematic review and meta-analysis","volume":"25","author":"Sze","year":"2016","journal-title":"Heart Lung Circ"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1350573\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T04:42:23Z","timestamp":1731559343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1350573\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":31,"alternative-id":["10.3389\/fcvm.2024.1350573"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1350573","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,14]]},"article-number":"1350573"}}